Ribociclib-d6

Ribociclib-d6 is the stable isotope-labeled counterpart of Ribociclib. Ribociclib is a highly specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and has been widely used in antitumor research. By inhibiting CDK4/6 activity, Ribociclib blocks phosphorylation of the retinoblastoma protein (Rb), thereby inducing cell cycle arrest and inhibiting tumor cell proliferation. In vitro studies show that Ribociclib has IC50 values of 10 nM and 39 nM for CDK4 and CDK6, respectively, and its activity against the cyclin B/CDK1 complex is more than 1000-fold lower. Due to its deuterated properties, Ribociclib-d6 is commonly used in isotope-tracing experiments for pharmacokinetic studies and metabolic analysis, helping scientists track the metabolic pathways and rates of the drug in biological systems. The dose or concentration used in experiments typically depends on the experimental design and research objectives.